Patents by Inventor Jinfa Du

Jinfa Du has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250074934
    Abstract: Provided are a type XVIII crystal of compound (3), and a preparation method therefor, a composition containing the crystal, and the use thereof. The type XVIII crystal shows good physical properties, such as easily prepared and crystal form stability, which is convenient for large-scale production and quality control of drugs, and is suitable as a crystal form of compound (3) in drug preparation.
    Type: Application
    Filed: January 17, 2023
    Publication date: March 6, 2025
    Inventor: Jinfa DU
  • Publication number: 20250066412
    Abstract: The present invention relates to the field of medicinal chemistry, and provides a crystal of 4?-substituted nucleoside, a preparation method therefor, a composition containing the crystal, and a use thereof. The crystal of the 4?-substituted nucleoside is a type-III crystal of compound (3). The type-III crystal shows excellent physical properties, such as easy preparation, stable crystal form and the like, and is convenient for large-scale production and quality control of drugs. The type-III crystal is suitable as a crystal form of compound (3) in drug preparation.
    Type: Application
    Filed: January 17, 2023
    Publication date: February 27, 2025
    Inventor: Jinfa DU
  • Patent number: 12161625
    Abstract: This application relates generally to certain substituted pyrrolizine compounds, and pharmaceutical compositions which inhibit HBV replication, and methods of making and using them.
    Type: Grant
    Filed: November 29, 2022
    Date of Patent: December 10, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Jinfa Du, Joshua A. Kaplan, Thorsten A. Kirschberg, Tetsuya Kobayashi, Scott E. Lazerwith, Rick Andrew Lee, Jonathan William Medley, Michael L. Mitchell, Philip Anthony Morganelli, Hyung-Jung Pyun, Sophia L. Shevick, Neil H. Squires, William J. Watkins
  • Patent number: 12121529
    Abstract: Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure: Also disclosed are methods of treatment, uses, and processes for preparing each of which utilize the compound represented by formula I.
    Type: Grant
    Filed: November 16, 2023
    Date of Patent: October 22, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Jinfa Du, Dhanapalan Nagarathnam, Michael Joseph Sofia, Peiyuan Wang
  • Publication number: 20240139227
    Abstract: Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure: Also disclosed are methods of treatment, uses, and processes for preparing each of which utilize the compound represented by formula I.
    Type: Application
    Filed: November 16, 2023
    Publication date: May 2, 2024
    Inventors: Jinfa Du, Dhanapalan Nagarathnam, Michael Joseph Sofia, Peiyuan Wang
  • Publication number: 20230277576
    Abstract: The present invention relates to a method for preventing or treating a coronavirus infectious disease, comprising administering to a patient in need thereof a therapeutically or prophylactically effective amount of a compound represented by formula (I) or pharmaceutically acceptable salts thereof. The compound represented by formula (I) is used for treating patients with novel coronavirus pneumonia, and shows obvious advantages in all of the clearance rate by viral nucleic acid test, the course of clearance, and the cure and discharge time.
    Type: Application
    Filed: February 20, 2021
    Publication date: September 7, 2023
    Inventors: Junbiao CHANG, Jinfa DU, Jiandong JIANG, Yuhuan LI
  • Publication number: 20230270719
    Abstract: This application relates generally to certain substituted pyrrolizine compounds, and pharmaceutical compositions which inhibit HBV replication, and methods of making and using them.
    Type: Application
    Filed: November 29, 2022
    Publication date: August 31, 2023
    Inventors: Jinfa Du, Joshua A. Kaplan, Thorsten A. Kirschberg, Tetsuya Kobayashi, Scott E. Lazerwith, Rick Andrew Lee, Jonathan William Medley, Michael L. Mitchell, Philip Anthony Morganelli, Hyung-Jung Pyun, Sophia L. Shevick, Neil H. Squires, William J. Watkins
  • Publication number: 20230151048
    Abstract: The present invention discloses a crystal form, a preparation method and an application of a 4?-substituted nucleoside compound I having the following structure, including salts, prodrugs, and compositions thereof. Animal pharmacokinetic studies demonstrated that the effective drug concentrations of Compound Ia and Compound Ig in HIV target cells, peripheral blood mononuclear cells (PBMC), were effective in inhibiting HIV replication after 7 and 5 days, respectively. Therefore, Compound I can be used as a long-acting drug for preventing and treating AIDS. R is selected from ethynyl, azide, and cyano groups, X is selected from hydrogen and fluorine, and B is selected from B1 and B2.
    Type: Application
    Filed: March 21, 2019
    Publication date: May 18, 2023
    Inventors: Junbiao CHANG, Jinfa DU, Kaikai ZHU, Kai WANG, Jianyong LI, Chunxia ZHANG
  • Patent number: 11642361
    Abstract: Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure: Also disclosed are methods of treatment, uses, and processes for preparing each of which utilize the compound represented by formula I.
    Type: Grant
    Filed: October 22, 2020
    Date of Patent: May 9, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Jinfa Du, Dhanapalan Nagarathnam, Michael Joseph Sofia, Peiyuan Wang
  • Patent number: 11578049
    Abstract: A compound represented by formula I or II. X represents a mono substituent on a benzene ring, and is selected from —H, —I, —Br, —Cl, —F, —CN, an amino, and a derivative thereof; R1 is a C2-10 alkyl, C2-10 alkyl substituted by cyclopropane or fluorine, except n-butyl; and M is an amine ion or metal ion.
    Type: Grant
    Filed: September 21, 2020
    Date of Patent: February 14, 2023
    Assignee: HENAN GENUINE BIOTECH CO., LTD.
    Inventors: Junbiao Chang, Jinfa Du, Kaikai Zhu, Kai Wang
  • Publication number: 20220024897
    Abstract: A 2-(2,4,5-substituted phenylamino) pyrimidine derivative, having the following chemical formula I:
    Type: Application
    Filed: October 11, 2021
    Publication date: January 27, 2022
    Inventors: Junbiao CHANG, Jinfa DU, Kaikai ZHU, Kai WANG, Jianyong LI, Chunxia ZHANG, Dongxu YI
  • Publication number: 20220002333
    Abstract: A crystalline form A of a compound I is a monoclinic system and a space group thereof is p21.
    Type: Application
    Filed: September 15, 2021
    Publication date: January 6, 2022
    Inventors: Junbiao CHANG, Jinfa DU, Dongxu YI
  • Publication number: 20210251957
    Abstract: This application relates generally to certain substituted pyrrolizine compounds, and pharmaceutical compositions which inhibit HBV replication, and methods of making and using them.
    Type: Application
    Filed: November 4, 2020
    Publication date: August 19, 2021
    Inventors: Jinfa DU, Joshua A. KAPLAN, Thorsten A. KIRSCHBERG, Tetsuya KOBAYASHI, Scott E. LAZERWITH, Rick Andrew LEE, Jonathan William MEDLEY, Michael L. MITCHELL, Philip Anthony MORGANELLI, Hyung-Jung PYUN, Sophia L. SHEVICK, Neil H. SQUIRES, William J. WATKINS
  • Publication number: 20210196741
    Abstract: Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure: Also disclosed are methods of treatment, uses, and processes for preparing each of which utilize the compound represented by formula I.
    Type: Application
    Filed: October 22, 2020
    Publication date: July 1, 2021
    Inventors: Jinfa Du, Dhanapalan Nagarathnam, Michael Joseph Sofia, Peiyuan Wang
  • Patent number: 10919908
    Abstract: The disclosure relates to a thienopyrimidinone derivative, or a pharmaceutically acceptable prodrug, salt, and solvate thereof. The derivative has the formula (I), where R represents hydrogen (H) or deuterium (D); R1 and R2 independently, at each occurrence, represent H, D, F, Cl, I, cyano group (CN), or N3, and when R represents H, R1 and R2 do not synchronously represent H; R3, R4 and R5 independently, at each occurrence, represent an alkyl group, a cycloalkyl group, a heterocyclic group, an aromatic ring group, or a heteroaryl ring group, which are substituted or unsubstituted.
    Type: Grant
    Filed: July 5, 2019
    Date of Patent: February 16, 2021
    Assignee: HENAN GENUINE BIOTECH CO., LTD.
    Inventors: Junbiao Chang, Jinfa Du
  • Publication number: 20210002244
    Abstract: A compound represented by formula I or II. X represents a mono substituent on a benzene ring, and is selected from —H, —I, —Br, —Cl, —F, —CN, an amino, and a derivative thereof; R1 is a C2-10 alkyl, C2-10 alkyl substituted by cyclopropane or fluorine, except n-butyl; and M is an amine ion or metal ion.
    Type: Application
    Filed: September 21, 2020
    Publication date: January 7, 2021
    Inventors: Junbiao CHANG, Jinfa DU, Kaikai ZHU, Kai WANG
  • Patent number: 10874640
    Abstract: This application relates generally to certain substituted pyrrolizine compounds, and pharmaceutical compositions which inhibit HBV replication, and methods of making and using them.
    Type: Grant
    Filed: May 3, 2019
    Date of Patent: December 29, 2020
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Jinfa Du, Joshua A. Kaplan, Thorsten A. Kirschberg, Tetsuya Kobayashi, Scott E. Lazerwith, Rick Andrew Lee, Jonathan William Medley, Michael L. Mitchell, Philip Anthony Morganelli, Hyung-Jung Pyun, Sophia L. Shevick, Neil H. Squires, William J. Watkins
  • Patent number: 10577359
    Abstract: The present invention provides (i) processes for preparing a 2?-deoxy-2?-fluoro-2?-methyl-D-ribonolactone derivatives, (ii) conversion of intermediate lactones to nucleosides with potent anti-HCV activity, and their analogues, and (iii) methods to prepare the anti-HCV nucleosides containing the 2?-deoxy-2?-fluoro-2?-C-methyl-ß-D-ribofuranosyl nucleosides from a preformed, preferably naturally-occurring, nucleoside.
    Type: Grant
    Filed: February 6, 2017
    Date of Patent: March 3, 2020
    Assignee: Gilead Pharmasset LLC
    Inventors: Byoung-Kwon Chun, Jinfa Du, Suguna Rachakonda, Peiyuan Wang
  • Publication number: 20200061024
    Abstract: This application relates generally to certain substituted pyrrolizine compounds, and pharmaceutical compositions which inhibit HBV replication, and methods of making and using them.
    Type: Application
    Filed: May 3, 2019
    Publication date: February 27, 2020
    Inventors: Jinfa Du, Joshua A. Kaplan, Thorsten A. Kirschberg, Tetsuya Kobayashi, Scott E. Lazerwith, Rick Andrew Lee, Jonathan William Medley, Michael L. Mitchell, Philip Anthony Morganelli, Hyung-Jung Pyun, Sophia L. Shevick, Neil H. Squires, William J. Watkins
  • Publication number: 20190330230
    Abstract: The disclosure relates to a thienopyrimidinone derivative, or a pharmaceutically acceptable prodrug, salt, and solvate thereof. The derivative has the formula (I), where R represents hydrogen (H) or deuterium (D); R1 and R2 independently, at each occurrence, represent H, D, F, Cl, I, cyano group (CN), or N3, and when R represents H, R1 and R2 do not synchronously represent H; R3, R4 and R5 independently, at each occurrence, represent an alkyl group, a cycloalkyl group, a heterocyclic group, an aromatic ring group, or a heteroaryl ring group, which are substituted or unsubstituted.
    Type: Application
    Filed: July 5, 2019
    Publication date: October 31, 2019
    Inventors: Junbiao CHANG, Jinfa DU